Novo shares moved lower on Monday. - Nichlas Pollier/Bloomberg News Novo Nordisk Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new blockbusters over the next few years but investors aren't yet convinced the Danish drugmaker is close to finding its next Ozempic. Novo's shares were down roughly 6% on Monday during the company's investor day in London. Most Read from The Wall Street Journal The New Ways to Thrive at Work Now, According to Adam Grant Paramount Discussed $1.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.